Torigen Pharmaceuticals and VerticalVet Enter into Preferred Partnership

Share Article

Agreement provides access to innovative companion animal cancer therapy to GPO members and their clients

News Image

Torigen Pharmaceuticals, Inc (Farmington, CT), an animal health biologics company, announced today that they have entered into a Preferred Partnership Agreement with VerticalVet, LLC(Cornelius, NC) to provide their 2,000+ clinic Group Purchasing Organization with access to Torigen. VerticalVet provides independent veterinary owners, practice managers, and technicians access to customized best practices education, real-time data insights, simplified marketing automation, and tailored partner solutions, such as Torigen’s Experimental Autologous Prescription Product.

This partnership will expand Torigen’s ability to deliver innovative companion animal cancer treatments to a larger patient population. Torigen offers experimental autologous cancer immunotherapy created from a surgically resected portion of tumor tissue that can be administered by both General Practitioners and Veterinary Oncologists. The combination of Torigen’s innovative products and VerticalVet’s vast network will allow more clinicians to be part of the veterinary oncology solution and provide more cancer treatment options to fight this devastating diagnosis.

“We are excited to partner with VerticalVet’s 2,000 veterinary hospitals nationwide,” says Ashley Kalinauskas, CEO and Co-Founder of Torigen Pharmaceuticals. “We believe that Torigen’s innovative cancer therapeutics and our diagnostic partnerships can provide more affordable and accessible treatment options to companion animal cancer patients.”

Every year, nearly ten million companion animals are diagnosed with cancer. Only 1 in 10 pet parents seek a consultation with a veterinary oncologist after receiving a cancer diagnosis from their family veterinarian. This partnership will make cancer treatments for tumor-based cancers more readily available to pet parents across the United States. Torigen’s mission is to empower veterinarians to be part of the solution through partnership and collaboration early in the diagnosis process. This is achieved by harnessing the power of the immune system to advance veterinary medicine.

“At VerticalVet, our aim is to connect our independent veterinary practice members with the best growth companies and pricing in the industry,” says John Wagoner, CEO and co-founder VerticalVet. “We are excited to finalize a partnership with Torigen and look forward to supporting their journey and continued success.”

“We’re excited to bring the latest in precision cancer treatments to our veterinary clinics,” added Ernie Ward, Chief Veterinary Officer, VerticalVet. “Our partnership with Torigen provides VerticalVet members access to individualized cancer therapy that promises to change the way veterinarians treat cancer.”

About Torigen’s Autologous Cancer Vaccine:
Torigen produces a personalized autologous prescription product for dogs, cats, and horses that uses the animal’s own tumor cells to create immunotherapy from a surgically resected portion of a tumor that can be used alone or in combination with chemotherapy and radiation. Torigen’s autologous prescription product is an experimental product regulated by the USDA Center of Veterinary Biologics under 9 CFR 103.3.

Torigen’s autologous prescription product is an active immunotherapy consisting of cells harvested from the patient’s own tumor. This whole-cell tumor vaccine is generated by a patented method to preserve cellular material and tumor- associated antigens and then mixed with immune-stimulating adjuvants. The objective is to increase the activation of tumor-specific T-cells resulting in an enhanced ability of the pet’s immune system to destroy cancer cells, stop or slow the growth of cancer cells, or delay cancer metastasis.

About Torigen Pharmaceuticals Inc:
Torigen is transforming pet cancer treatment by harnessing the pet's immune system to create personalized cancer immunotherapies, making pet cancer treatment more accessible and more affordable. Torigen recognizes the instrumental role pets play in our families and is determined to extend the lives of companion animals despite a cancer diagnosis. With over 50% of all dogs over the age of 10 dying from cancer, Torigen is dedicated to providing affordable and effective cancer care solutions for all companion animals. Torigen is a spin-out from the University of Notre Dame and backed by Werth Family Investment Associates, Connecticut Innovations, Emerald Development Managers, Ironwood Capital, Advantage Capital, The University of Connecticut, The University of Notre Dame, SoGal Ventures, Gaingels, and other prominent investors. For more information visit

About VerticalVet:
Started by industry veterans with practice, industry, distribution, and manufacturing
experience, Dr. Hank Swartz and John Wagoner joined forces to vertically align all of the tools and resources clinics would need under one roof. However, the goal was never to be “just another discount club.” VerticalVet is a Group Resource Community (GRC). We provide independent veterinary owners, practice managers, and technicians access to customized best practices education, real-time data insights, simplified marketing automation, and tailored partner solutions. The VerticalVet community is diverse, inclusive, and focused on building a better normal together, allowing members to have the peace of mind to focus on what matters most: providing excellent patient care. We didn't stop there! In 2022, VerticalVet joined forces with Vimians Group, Veterinary Services segment, VetFamily! Together, VerticalVet is now part of a global and diversified group of innovation-driven companies with a shared passion for making a positive impact through improving animal health.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Kallassay
Visit website